The 3-D reconstruction of the mesh implant and nearby anatomical structures (see image) are developed using 3-D Slicer, an open source software platform for medical image informatics, and are based on static MR images obtained before surgery and then again after the procedure.
Using MR images obtained at 3 months, researchers were able to 3-D-reconstruct the course of the mesh and its arms in the pelvis in five out of six subjects, Dr. Brocker noted. Using 1-year MRIs, they were able to produce images of satisfactory quality for two of the subjects.
Being able to see the actual position of the implant and its distance from nerves, vessels, and other surrounding structures is one of the key advantages of using an MR-visible mesh, Dr. Brocker said. In addition, the visibility provided by the technique might allow for better planning of revision surgeries, and may help in managing complications.
Dr. Brocker helped develop the mesh, and in an interview with Urology Times, said that part of the reason for exploring the concept of visible meshes related to concerns that had been raised regarding vaginal mesh implants.
In January 2016, the FDA strengthened its data requirements for manufacturers to help to address the significant risks associated with surgical mesh for repair of pelvic organ prolapse.
As a next step in research, Dr. Brocker and colleagues plan to evaluate MR-visible meshes of different sizes and dimensions to determine any potential differences on 3-D-reconstruction or clinical outcomes.
Dr. Brocker said she hopes her group’s results will encourage others “not to be scared of the method... Using an MR-visible mesh in further research can help us better understand how alloplastic materials work in the female pelvic floor.”
Dr. Brocker’s presentation was awarded the Best in Category Prize in Imaging at the ICS meeting. The research represented a collaboration between investigators at the University of Heidelberg and the University of Michigan, Ann Arbor.
Dr. Brocker has received speaking honoraria and research funding from Serag Wiessner (Naila, Germany), though none of those funds were used to fund this trial.
More from Urology Times:
To get weekly news from the leading news source for urologists, subscribe to the Urology Times eNews.